COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH REDUCED EJECTION FRACTION PATIENTS IN INDIAN HEALTHCARE SETTING

被引：0
|
作者：
Gokhale, S. [1 ]
Partha, G. [2 ]
Proudfoot, C. [3 ]
Anand, S. [1 ]
机构：
[1] Novartis Healthcare Pvt Ltd, Mumbai, Maharashtra, India
[2] Novartis Healthcare Pvt Ltd, Hyderabad, India
[3] Novartis Pharma AG, Basel, BS, Switzerland
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC142
引用
收藏
页码：S115 / S115
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF SYMPTOMATIC CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL
    Alarcao, J.
    Ascencao, R.
    Costa, J.
    Gouveia, M.
    Borges, M.
    VALUE IN HEALTH, 2018, 21 : S104 - S104
  • [22] Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
    Giorgi, Mariano A.
    Boissonnet, Carlos P.
    Luque, Paula Soledad
    Piastrella, Jimena
    Porley, Carlos
    Ditata, Fernanda
    Volman, Sergio
    HEALTH ECONOMICS REVIEW, 2023, 13 (01)
  • [23] Comparative Cost-Effectiveness of Sacubitril-Valsartan, Dapagliflozin, and Empagliflozin in Heart Failure With Reduced Ejection Fraction
    Parikh, Neil U.
    Dixit, Neal
    Ziaeian, Boback
    Fonarow, Gregg C.
    CIRCULATION, 2022, 146
  • [24] Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context
    D'Angiolella, Lucia S.
    Cortesi, Paolo A.
    Pitotti, Claudia
    Ritrovato, Daniela
    Mantovani, Lorenzo G.
    Senni, Michele
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (11) : 1551 - 1553
  • [25] Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis
    Zaca, Valerio
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2018, 19 (10) : 597 - 605
  • [26] The cost-effectiveness of sacubitril/valsartan (LCZ696) in the treatment of patients with heart failure with reduced ejection fraction in Norway
    Gundersen, V.
    Eklund, O.
    Hancock, E.
    Hussain, R.
    Ohna, A.
    EUROPEAN HEART JOURNAL, 2016, 37 : 203 - 203
  • [27] Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand
    Krittayaphong, Rungroj
    Permsuwan, Unchalee
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2018, 18 (05) : 405 - 413
  • [28] Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand
    Rungroj Krittayaphong
    Unchalee Permsuwan
    American Journal of Cardiovascular Drugs, 2018, 18 : 405 - 413
  • [29] THE COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN ALTERNATIVE AGE GROUPS
    Hancock, E.
    Trueman, D.
    Alexopoulos, S. T.
    Gielen, V
    VALUE IN HEALTH, 2016, 19 (07) : A655 - A655
  • [30] REAL-WORLD COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL
    Afonso-Silva, M.
    Laires, P. A.
    VALUE IN HEALTH, 2019, 22 : S545 - S545
12345